Despite an increase in the sample size (9 additional companies reviewed in 2023), payment practices within the Life Sciences and MedTech sectors remained virtually unchanged year-on-year, suggesting that systemic improvements in payment behaviour are not occurring. This lack of movement highlights persistent challenges, even with a broader range of companies included in the assessment.
Payment practices in the Life Sciences and Medical Technology sectors show no significant improvement, remaining static at 59.8/100 despite reviewing more companies. You can use this late payment calculator to work out interest and compensation owed.